top of page
Multiple Myeloma Clinical Trials - Currently Recruiting
2022- (R) NCT05204160
Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
2021- (R) NCT04771078
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
2021 - (R) NCT04879043
Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
2021 - (R) NCT04855136
Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
2021 - (R) NCT04756726
Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
2021 - (R) NCT04722146
Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
2020- (Active) NCT04649359
Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
2020 - (R) NCT04570631
Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
2020 - (R) NCT04483206
Phase 1: Personalized Autologous Transplant for Multiple Myeloma
2020 - (R) NCT04445701
Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
2019- (R) NCT04126200
Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)
2019- (Active) NCT03848845
Phase 1/2: GSK2857916 in Combination With Pembrolizumab in RRMM Myeloma- DREAMM 4
2019 - (R) NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - (R) NCT04123418
Phase 1: A Study of WVT078 in Patients With Multiple Myeloma (MM)
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2019 - (R) NCT03858205
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Multiple Myeloma Patients
2018- (R) NCT03777410
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
2018- (R) NCT03399799
Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
2018- (Active) NCT03544281
Phase 2: GSK2857916 /Len/Dex Vs GSK2857916/Bortezomib/Dex - RRMM Myeloma - DREAMM 6
2018 (R) NCT03424603
Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, B-Cell Malignancies
2018 - (R) NCT03761108
Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
2018 - (R) NCT03732703
Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
2018 - (R) NCT03651128
Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
2018 - (R) NCT03601078
Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
2018 - (R) NCT03486067
Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
NDMM
MGUS/SMM
bottom of page